From Sick-Care to Health-Care
Precision medicine's real promise is not better treatment, but earlier action!
For decades, the healthcare system has been misnamed. What we call "healthcare" is, in practice, mostly sick-care: a system designed to respond after symptoms appear, after disease has progressed, after patients have already entered the expensive, frightening, and often irreversible parts of the clinical journey.
We built magnificent hospitals, highly specialized therapeutic franchises, and increasingly sophisticated reimbursement machinery around the treatment of illness. But we have not built an equally powerful system around the maintenance of health.
Precision medicine may finally change that.
Not because it gives us more data. Not because sequencing is getting cheaper. Not even because AI is getting better. Those are enablers. The deeper shift is that precision medicine technologies are giving healthcare something it has historically lacked: the ability to see risk, disease, and therapeutic opportunity earlier, more clearly, and more individually.
That is what turns sick-care into healthcare.
Precision medicine has been too narrowly defined
For many people, precision medicine still means matching a cancer patient to a targeted therapy based on a genomic alteration. That was the first act, and it was transformative. EGFR, BRAF, ALK, HER2, BRCA, NTRK, KRAS — each became more than a biomarker. Each became proof that biology could reorganize clinical decision-making.
But the next act is bigger. The future of precision medicine is not just "right drug, right patient." It is: Right patient. Right risk. Right test. Right time. Right intervention.
That means identifying cancer when it is still curable. Diagnosing rare disease before a child spends years in a diagnostic odyssey. Detecting recurrence before imaging can see it. Understanding inherited risk before symptoms appear. Choosing therapy based not only on tumor type, but on biology, immune context, resistance mechanisms, and molecular evolution.
In other words, precision medicine is moving upstream. And upstream is where healthcare becomes healthcare.
MCED is a symbol of the shift
Multi-cancer early detection, or MCED, is one of the clearest examples of this new paradigm.
The current cancer system is largely organized around symptoms, imaging findings, organ-specific screening, and specialist referral pathways. That works for some cancers. It fails many others. Too many cancers are still detected late, when treatment is more toxic, more expensive, and less likely to be curative.
MCED challenges that model. It asks a provocative question: what if a simple blood test could identify a cancer signal before the patient feels sick, before the tumor declares itself clinically, and before the system has shifted into crisis mode?
If MCED works at scale, the bottleneck will not be the blood draw. It will be everything around it: confirmatory diagnostics, imaging capacity, primary care workflows, patient communication, follow-up algorithms, reimbursement, guidelines, and liability. The technology may be molecular, but the transformation required is organizational.
That is why MCED should not be evaluated only as another diagnostic category. It should be viewed as a stress test for whether the healthcare system is capable of acting preventively.
The same is true for MRD in oncology. The ability to detect molecular recurrence before radiographic relapse creates a profound opportunity: intervene earlier, monitor more intelligently, and potentially change the shape of the cancer journey. But again, the test alone is not the product. The product is the new clinical workflow the test makes possible.
Whole-genome sequencing (WGS) can end diagnostic odysseys
Rare disease is another powerful example. For families affected by rare genetic conditions, the traditional system often fails in a particularly painful way. Patients move from specialist to specialist, test to test, year after year, while symptoms progress and uncertainty compounds. This is not just inefficient. It is cruel.
Whole-genome sequencing offers a different model.
Rather than interrogating the patient one gene, one panel, or one hypothesis at a time, WGS allows the system to ask a broader biological question earlier: is there a genetic explanation for this presentation?
For rare disease patients, especially children, that can change everything. A molecular diagnosis can end uncertainty, guide management, connect patients to trials or emerging therapies, inform reproductive decisions, and help families understand what they are facing.
The strategic point is larger: WGS turns diagnosis from a sequential scavenger hunt into a platform capability.
That matters because rare disease is only one application. Over time, broader genomic profiling could inform pharmacogenomics, inherited risk, carrier status, cancer predisposition, newborn screening, and long-term prevention strategies. We should not think of WGS as a single test. We should think of it as clinical infrastructure.
The winners will build systems, not just tests
The next generation of precision medicine companies will not win simply because their assay is analytically elegant. They will win because they solve adoption.
That means generating evidence, earning reimbursement, integrating into clinical workflows, educating physicians, supporting patients, building data infrastructure, and creating confidence across regulators, payors, providers, and health systems.
This is why the "tools and diagnostics" part of precision medicine is so strategically important. Therapeutics capture much of the value and public imagination, but diagnostics often determine whether the right patient is ever found, whether disease is detected early enough, and whether care is directed intelligently.
In that sense, diagnostics are not ancillary to the precision medicine revolution. They are the operating system.
But the industry has sometimes undersold itself. We talk about sensitivity, specificity, turnaround time, and cost per sample. Those matter. But the larger value proposition is that these technologies can reshape patient journeys, clinical economics, and healthcare capacity.
A late-stage cancer diagnosis is not just a clinical tragedy. It is a failure of system timing.
A five-year rare disease odyssey is not just bad luck. It is a failure of diagnostic architecture.
A patient receiving the wrong therapy because molecular testing was not ordered is not just an information gap. It is a workflow failure. Precision medicine gives us the tools to fix these failures.
The hard part is not the science anymore
This is not to say the science is solved. It is not. MCED still needs rigorous evidence, thoughtful implementation, and careful communication around false positives, false negatives, and downstream workups. WGS still requires interpretation, infrastructure, equity of access, and clinical actionability. MRD still needs indication-specific evidence and therapeutic decision frameworks.
But increasingly, the limiting factor is not whether the technology can generate signal. It is whether the system can absorb that signal and act on it.
That is a leadership problem. Boards, CEOs, health systems, payors, and policymakers need to stop treating precision medicine as a set of niche innovations and start treating it as a redesign agenda for healthcare.
The questions should be:
- How do we pay for prevention when the savings accrue later?
- How do we integrate molecular testing into routine care without overburdening physicians?
- How do we build evidence standards that are rigorous without being paralyzing?
- How do we ensure that earlier detection does not become a privilege for wealthy patients?
- How do we align diagnostics, therapeutics, data, and care delivery into one coherent system?
These are the questions that will determine whether precision medicine remains a high-end specialty capability or becomes the foundation of modern healthcare.
From reactive medicine to anticipatory medicine
The healthcare system we have today is reactive. Precision medicine enables something different: anticipatory medicine.
- A system that sees risk before disease.
- A system that detects disease before symptoms.
- A system that diagnoses earlier, treats more precisely, monitors continuously, and learns from every patient.
That is the promise.
And it is why I remain deeply optimistic about this space, despite the fact that it's been hard, and it won't be easy in the future. I am optimistic because the direction of travel is right.
The old system waits for disease to become visible. The new system will make biology visible earlier.
That shift may sound subtle. It is not. It is the difference between treating heart attacks and managing cardiovascular risk. Between late-stage cancer therapy and early cancer interception. Between years of rare disease uncertainty and a molecular diagnosis in infancy. Between sick-care and healthcare. Precision medicine will not transform healthcare simply by making tests better. It will transform healthcare by changing when the system knows, when it acts, and what it believes is possible.
That is the revolution worth championing!